Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China
Source: Streetwise Reports  (8/31/21)
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. More >

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline
Source: Streetwise Reports  (8/31/21)
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. More >

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21
Source: Streetwise Reports  (8/30/21)
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. More >

Poseida Shares Point Higher After FDA Clears NDA for Relapsed/Refractory Multiple Myeloma Treatment Candidate
Source: Streetwise Reports  (8/30/21)
Shares of Poseida Therapeutics traded 10% higher after the company reported that the U.S. Food and Drug Administration granted clearance for its Investigational New Drug Application for P-BCMA-ALLO1, an allogeneic CAR-T candidate for use in treating relapsed/refractory multiple myeloma. More >

Bolt Bio Partners With Innovent Biologics to Create Three New Cancer Treatments
Source: Streetwise Reports  (8/28/21)
Shares of Bolt Biotherapeutics Inc. traded nearly 10% higher after the company reported it is collaborating with Innovent Biologics to develop three new oncology Boltbodyâ„¢ ISAC programs. More >

With November PDUFA Date, FDA Could Approve Biotech's Lead Cell Therapy Soon
Source: Streetwise Reports  (8/24/21)
A BTIG report noted that Legend Biotech's cilta-cel has the potential "to take significant market share within the relapsed-refractory multiple myeloma market and establish a best-in-class profile." More >

Biopharma's Amino Acid Compound Shows Anti-Inflammatory Effect
Source: Streetwise Reports  (8/23/21)
Studies suggest that Galmed Pharmaceuticals' Amilo-5MER has "therapeutic potential in a number of inflammatory diseases," according to an H.C. Wainwright & Co. report. More >

Trillium Receives US$2.26B Buyout Bid, Shares Trade 190% Higher
Source: Streetwise Reports  (8/23/21)
Trillium Therapeutics shares traded 190% higher after the company reported it agreed to be acquired by pharmaceutical giant Pfizer Inc. for $18.50 per share in cash. More >

Specialty Pharma's Q2/21 Results 'Fundamentally Ahead of Expectations'
Source: Streetwise Reports  (8/23/21)
A ROTH Capital Partners report noted that Assertio Therapeutics' business model is starting to gain traction. More >

Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials
Source: Streetwise Reports  (8/18/21)
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. More >

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates
Source: Streetwise Reports  (8/18/21)
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. More >

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales
Source: Streetwise Reports  (8/18/21)
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. More >

Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher
Source: Streetwise Reports  (8/16/21)
Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease. More >

Coverage Initiated on Developer of Treatment for Myelofibrosis, GvHD, COVID-19
Source: Streetwise Reports  (8/11/21)
A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time." More >

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
Source: Streetwise Reports  (8/10/21)
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors. More >

Fulcrum Shares Soar on Positive Interim Data in Phase 1 Sickle Cell Disease Study
Source: Streetwise Reports  (8/10/21)
Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial. More >

Cortexyme Expects to Release Positive Topline Data from Ph. 2/3 Alzheimer's Trial by Late Autumn
Source: Streetwise Reports  (8/9/21)
Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials. More >

US-Based Biopharma 'In Full Reset Mode,' Analyst Says
Source: Streetwise Reports  (8/4/21)
An H.C. Wainwright & Co. report notes that Agios Pharmaceuticals "is rapidly rebooting and has made critical progress on various fronts." More >

Biopharma Makes 'Solid Clinical Progress' in Q2/21
Source: Streetwise Reports  (8/4/21)
The highlights of Oryzon Genomics' Q2/21 clinical advancements were recapped in a Roth Capital Partners report. More >

Novavax Shares Get a Boost as EC Orders up to 200 Million Doses of Its COVID-19 Vaccine
Source: Streetwise Reports  (8/4/21)
Novavax Inc. shares traded nearly 19% higher after the company reported the finalization of an advance purchase agreement with the European Commission to provide up to 200 million doses of its COVID-19 Vaccine. More >

Translate Bio Shares Rise 29% on Sanofi's $3.2 Billion Buyout Bid
Source: Streetwise Reports  (8/3/21)
Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion. More >

Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot
Source: McAlinden Research for Streetwise Reports  (8/2/21)
McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow. More >

Annovis Shares Rise on Positive Phase 2 Alzheimer's and Parkinson's Disease Trial Results
Source: Streetwise Reports  (8/2/21)
Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases. More >

Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial
Source: Streetwise Reports  (7/28/21)
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report. More >

Biopharma Creates New Business Unit Ahead of Commercial Product Launch
Source: Streetwise Reports  (7/28/21)
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report. More >